SCHEMBL496019

SCHEMBL496019

CCOC(=O)c1ccc(Cl)nc1NC1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR2F2 P24468 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
S1PR2 O95136 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
XBP1 P17861 1/20 0.53
RAB9A P51151 1/20 0.53
PPP1CA P62136 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
ALOX15 P16050 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.46
CASP3 P42574 4/20 0.46
PDE4B Q07343 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
ADORA3 P0DMS8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12936321 0.87 RIPK1 (0.49) ALDH1A1KDM4EL3MBTL1TDP1OPRK1
SCHEMBL22860320 0.86 RIPK1 (0.47) ALDH1A1KDM4EL3MBTL1TDP1OPRK1
SCHEMBL495713 0.85 NR2F2 (0.53) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL10129609 0.84 FER (0.45) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL4406621 0.83 SYK (0.46) ALDH1A1L3MBTL1
SCHEMBL29501978 0.82 NR2F2 (0.63) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL20299361 0.82 NR2F2 (0.63) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL10129614 0.81 NR2F2 (0.40) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL4070421 0.81 NR2F2 (0.62) NR2F2NPSR1MEN1NPC1S1PR2
SCHEMBL495797 0.80 KMT2A (0.43) MEN1ALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 NR2F2 2185/4885NPSR1 513/4885MEN1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.